Core Center of Excellence in Hematology

总体描述(由申请人提供)： NIDDK血液学卓越核心中心(CCEH)为弗雷德·哈钦森癌症研究中心(FHCRC)和华盛顿大学(UW)的研究人员提供资源。这些资源旨在克服限制个体研究人员分离、功能鉴定和操纵造血干细胞及其后代的能力的障碍。这些限制中的主要限制是无法从患者、正常个体和大型动物那里获得足够数量的特定细胞群体。大规模细胞处理技术解决了这一限制，它从大量的人、狗和非人类灵长类动物的血液和骨髓中分离出特定的细胞群体。该中心还保存着血液疾病患者的冷冻保存样本，并确定和维护所有同种异体移植组件的数据库。此外，我们目前正在开发犬胚胎干细胞系，供CCEH成员使用。克隆分析提供了移植受者嵌合体的测量方法，并使用LAM-PCR对基因标记细胞进行克隆分析。我们还有分子生物学咨询和教程。载体生产设计和生产逆转录病毒、慢病毒和泡沫病毒载体，用于标记和转导细胞。这有助于追踪基因标记的细胞，并为实验设计提供咨询。NOD/SCID分析保持了对特定细胞群体的增殖和分化潜力的体内最先进读数。它维护和提供各种免疫缺陷小鼠繁育种群的质量控制，执行所有注射和组织采集，并提供实验设计咨询。综上所述，研究人员有可能分离出感兴趣的细胞，标记它们，改变它们的功能，并在体外和体内准确地检测和定量它们的后代。这四个项目由行政部门监督和支持，行政部门由CCEH主任Beverly Torok-Storb和副主任Shelly Heimfeld领导。来自外部和内部顾问的行政指导还支持试点研究和充实计划。有30多名基于FHCRC-UW的研究人员使用这些资源。超过90%的赠款支持来自美国国立卫生研究院

DESCRIPTION, OVERALL (provided by applicant): This NIDDK Core Center of Excellence in Hematology (CCEH) provides resources to investigators at the Fred Hutchinson Cancer Research Center (FHCRC) and University of Washington (UW). These resources are designed to overcome obstacles that limit the ability of individual investigators to isolate, functionally characterize, and manipulate hematopoietic stem cells and their progeny. Primary among these limitations is the inability to obtain sufficient quantities of defined cell populations from patients, normal individuals and large animals. This limitation is addressed by the Large-Scale Cell Processing which isolates specific populations of cells from large volumes of human, canine, and non-human primate blood and marrow. This Core also maintains a Repository of cryopreserved specimens from patients with hematologic diseases, and characterizes and maintains a database on all allogeneic transplant components. In addition We are currently developing canine embryonic stem cell lines for the use of CCEH members. the Clonal Analysis provides measures of chimerism in transplant recipients and clonal analysis of gene marked cells using LAM-PCR. We also have molecular biology consultation and tutorials. Vector Production designs and produces retrovirus, lentivirus, and foamy virus vectors for marking and transducing cells. This aids in the tracking of gene-marked cells and provides consultation for experimental design. The NOD/SCID Assay maintains a state-of-the-art in vivo readout of the proliferative and differentiative potential of defined populations of cells. This maintains and provides quality control for breeding stocks of various immunodeficient mice, performs all injections and tissue harvesting, and provides experimental design consultation. Taken together these make it possible for investigators to isolate cells of interest, mark them, alter their function, and accurately detect and quantitate their progeny in vitro and in vivo. These four are supervised and supported by the Administrative one under the direction of CCEH Director Beverly Torok-Storb and Associate Director Shelly Heimfeld. Administrative guidance from external and internal advisors also supports Pilot Studies and an Enrichment Program. There are more than 30 FHCRC-UW based researchers using these esources. Greater than 90%of all grant support comes from the NIH